FDC has launched two variants of the COVID-19 drug, Favipiravir - PiFLU and Favenza - which will be used to treat mild to moderate cases of COVID-19 in India. The company’s PiFLU and Favenza is currently available across the country. Earlier this year, the Drug Controller General of India (DCGI) approved the use of Favipiravir, an off patent, oral anti-viral drug that has been shown to quicken clinical recovery in COVID-19 patients with mild to moderate symptoms. It is a broad spectrum anti-viral agent, and selectively inhibits RNA polymerase of influenza and SARCOV-2 virus and prevents viral replication.
Besides, the company has also increased the production and availability of its brand of balanced electrolyte drink ‘Enerzal and Electral as according to ASPEN guidelines, 03 litres of fluid intake in a day (60 to 120 ml in every 30 min) helps in speedy recovery of people who are home quarantined.
FDC is engaged in manufacture of specialized formulations, and oral rehydration salts (ORS).
